Lyudmila Bazhenova, MD, PhD

Penetration of molecular testing for non–small cell lung cancer in the US is not at 100%, according to Lyudmila Bazhenova, MD, FASCO.

Lyudmila Bazhenova, MD, and Federico Albrecht, MD, detailed the importance of using real-world evidence to inform treatment for patients with EGFR-mutated non–small cell lung cancer.

Drs Lyudmila Bazhenova and Federico Albrecht comment on the significance of real-world data collection in EGFR-mutated non–small cell lung cancer and suggest what can be done to increase the rates of real-world studies conducted.

Recommendations for how to best treat patients with EGFR-mutated non–small cell lung cancer when there are discrepancies between clinical trial data and real-world evidence.

Information provided by real-world data that is noted to be the most valuable to thoracic oncologists and others who manage patients with EGFR-mutant non–small cell lung cancer.

Drs Lyudmila Bazhenova and Federico Albrecht comment on the pros and cons of real-world evidence to guide treatment decisions for patients with EGFR-mutant non–small cell lung cancer.

Federico Albrecht, MD, reacts to limitations regarding the designs and outcomes of randomized controlled trials in EGFR-mutant non–small cell lung cancer and describes his interest in collecting real-world data.

CancerNetwork® sat down with Lyudmilia Bazhenova, MD, at the 2021 World Conference on Lung Cancer to discuss differences in outcomes with immunotherapy agents in patients with wild-type and EGFR exon 20 insertion–positive non–small cell lung cancer.

CancerNetwork® sat down with Lyudmilia Bazhenova, MD, at the 2021 World Conference on Lung Cancer to talk about the feasibility of immunotherapy trials in wild-type and EGFR exon 20 insertion non–small cell lung cancer.

Dr. Lyudmila Bazhenova presents a recently published article by Nazha B, et al., “Benefits and limitations of real-world evidence: lessons from EGFR mutation-positive non-small-cell lung cancer.”

CancerNetwork® sat down with Lyudmila Bazhenova, MD, at the 2021 World Conference on Lung Cancer to talk about immunotherapy response in patients with EGFR exon 20 insertion mutations.